MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Candid Therapeutics
Organization & Developments: Candid Therapeutics
Parents
Candid Therapeutics
Children
*Advanced T-cell engager antibodies, precisely redirecting T-cells to selectively eliminate autoreactive B-cells
*Candid Therapeutics is a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for B-cell depletion to treat autoimmune diseases.
2024: Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies
2024: Candid, with $370M, sets out to prove bispecifics’ worth in autoimmune disease
2025: Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
Address, enabling patients with autoimmune diseases to experience transformative efficacy and improved therapeutic outcomes.
Jumps
Finance & Acquisition: Candid Therapeutics
Key People: Candid Therapeutics